Dasatinib N-oxide-d8

• UNSPSC Description:

  Dasatinib N-oxide-d8 is the deuterium labeled Dasatinib N-oxide. Dasatinib N-oxide is a minor metabolite of Dasatinib. Dasatinib is a potent and orally active dual Src/Bcr-Abl inhibitor[1][2].

• Target Antigen:

  Drug Metabolite; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Metabolic Enzyme/Protease;Others

• Field of Research:

  Cancer

• Smiles:

  OCC[N+]1([O-])C([2H])([2H])C([2H])([2H])N(C2=NC(C)=NC(NC3=NC=C(C(NC4=C(C)C=CC=C4Cl)=O)S3)=C2)C([2H])([2H])C1([2H])[2H]

• Molecular Weight:

  512.05

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Christopher LJ, et, al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008 Jul;36(7):1357-64.|[3]Furlong MT, et, al. A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study. J Pharm Biomed Anal. 2012 Jan 25;58:130-5.

• Shipping Conditions:

  Room temperature

• CAS Number:

  1189988-36-0